Genesis Drug Discovery & Development

Genesis Drug Discovery & Development (GD3) is a privately held, revenue-generating CRO founded in 2009, offering end-to-end services from early-stage discovery to clinical trial management. Its business model is centered on providing outsourced research and development capabilities to biopharmaceutical clients, encompassing medicinal chemistry, in vitro/in vivo biology, DMPK, disease modeling, and preclinical toxicology. The company positions itself as a specialized partner with deep expertise in specific therapeutic areas like oncology, metabolic diseases, and ocular disorders, aiming to de-risk and accelerate client pipelines.

Integrated CRO service platform encompassing medicinal chemistry, synthetic chemistry, in vitro/in vivo biology, DMPK, specialized disease modeling (ocular, oncology PDX), and preclinical toxicology to support drug discovery from target ID through IND filing.

Operates in the highly competitive preclinical and clinical CRO sector. Competitors range from massive public companies like Charles River Laboratories, LabCorp, and IQVIA to numerous smaller, specialized service providers. GD3 competes on integrated services, scientific expertise in specific areas, and presumably personalized client service.